162 related articles for article (PubMed ID: 36853299)
1. Comparison of GATA-3, Mammaglobin and GCDFP-15 Expression in Primary, Metastatic and Triple Negative Breast Carcinomas: An Indian Scenario.
Rao M; Khade S; Chaudhary R; Singh P; Yadav G; Elhence P; Nalwa A; Sharma R; Goel AD
Asian Pac J Cancer Prev; 2023 Feb; 24(2):509-515. PubMed ID: 36853299
[TBL] [Abstract][Full Text] [Related]
2. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry.
Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996
[TBL] [Abstract][Full Text] [Related]
3. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.
Zombori T; Cserni G
Pathol Oncol Res; 2018 Apr; 24(2):259-267. PubMed ID: 28470571
[TBL] [Abstract][Full Text] [Related]
5. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
6. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
[TBL] [Abstract][Full Text] [Related]
7. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections.
Kandalaft PL; Simon RA; Isacson C; Gown AM
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):609-614. PubMed ID: 26447897
[TBL] [Abstract][Full Text] [Related]
8. Comparison of GATA-3, mammaglobin, GCDFP-15 expression in breast carcinoma in serous effusions: A cell-block micro-array study.
El Hag MI; Hag AM; Ha JP; Michael CW
Pleura Peritoneum; 2017 Sep; 2(3):143-148. PubMed ID: 30911644
[TBL] [Abstract][Full Text] [Related]
9. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas.
Yang M; Nonaka D
Mod Pathol; 2010 May; 23(5):654-61. PubMed ID: 20173733
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
Liu H; Shi J; Prichard JW; Gong Y; Lin F
Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
[TBL] [Abstract][Full Text] [Related]
11. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
12. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer.
Huo L; Zhang J; Gilcrease MZ; Gong Y; Wu Y; Zhang H; Resetkova E; Hunt KK; Deavers MT
Histopathology; 2013 Jan; 62(2):267-74. PubMed ID: 22963676
[TBL] [Abstract][Full Text] [Related]
13. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
14. Are mammaglobin and GCDFP-15 sensitive markers for diagnosis of metastatic basal-like triple negative breast carcinomas?
Rakhshanı N; Daryakar A
Turk Patoloji Derg; 2014; 30(1):18-22. PubMed ID: 24272937
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
16. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.
Bhargava R; Beriwal S; Dabbs DJ
Am J Clin Pathol; 2007 Jan; 127(1):103-13. PubMed ID: 17145637
[TBL] [Abstract][Full Text] [Related]
17. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
[TBL] [Abstract][Full Text] [Related]
18. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin.
Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P
Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362
[TBL] [Abstract][Full Text] [Related]
19. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer.
Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G
Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195
[TBL] [Abstract][Full Text] [Related]
20. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors.
Chia SY; Thike AA; Cheok PY; Tan PH
Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
